安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- People With Severe Diabetes Are Cured in Small Trial of New . . .
Patients with type 1 must inject carefully calibrated doses of the hormone to substitute for the insulin their body is missing Type 1 is different from the more common type 2 diabetes, which usually occurs later in life Controlling insulin levels is a constant, often costly effort Elevated blood sugar levels can damage the heart, kidneys
- Orforglipron, an oral GLP-1, cut HbA1c, weight at 40 weeks . . .
CHICAGO — Orforglipron, a novel nonpeptide, small molecule oral GLP-1, reduced HbA1c at 40 weeks for patients with type 2 diabetes, according to results of the phase 3 ACHIEVE-1 trial
- Off-the-shelf stem cell therapy for type 1 diabetes yields . . .
Twelve people with type 1 diabetes who received an investigational off-the-shelf stem cell therapy were able to produce their own insulin and keep healthy blood glucose levels for at least one
- People with Severe Type 1 Diabetes are Cured in Small Trial . . .
"A single infusion of a stem cell-based treatment may have cured 10 out of 12 people with the most severe form of Type 1 diabetes," reports the New York Times "One year later, these 10 patients no longer need insulin The other two patients need much lower doses " The experimental treatment, cal
- Tirzepatide as Compared with Semaglutide for the Treatment of . . .
In this phase 3b, open-label, controlled trial, adult participants with obesity but without type 2 diabetes were randomly assigned in a 1:1 ratio to receive the maximum tolerated dose of
- Vertex launches pivotal trial for stem-cell derived islet . . .
On Monday, Vertex made a monumental announcemen t Their Phase 1 2 trial for VX-880 is converting to a Phase 1 2 3 pivotal trial, enrolling 50 total people It’s a huge first for type 1 diabetes (T1D) It’s the first time a scalable cure for some people with T1D is entering a Phase 3 clinical trial
- Expanded FORWARD Trial Demonstrates Continued Potential for . . .
The trial has been further expanded to enroll a total of approximately 37 participants in order to generate clinical data that will support the goal of making VX-880 available for people living with type 1 diabetes in the future
|
|
|